Janus Henderson Group PLC Has $60.32 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Janus Henderson Group PLC trimmed its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 12.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 219,337 shares of the biopharmaceutical company's stock after selling 30,103 shares during the quarter. Janus Henderson Group PLC owned about 0.17% of Alnylam Pharmaceuticals worth $60,324,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of ALNY. Eventide Asset Management LLC grew its stake in shares of Alnylam Pharmaceuticals by 157.9% in the third quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company's stock worth $61,698,000 after acquiring an additional 137,333 shares during the last quarter. Los Angeles Capital Management LLC grew its position in Alnylam Pharmaceuticals by 11,433.4% in the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company's stock worth $37,684,000 after purchasing an additional 135,829 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of Alnylam Pharmaceuticals by 92.5% during the 2nd quarter. AQR Capital Management LLC now owns 271,619 shares of the biopharmaceutical company's stock worth $65,862,000 after purchasing an additional 130,482 shares during the period. Deerfield Management Company L.P. Series C acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at about $29,111,000. Finally, Avoro Capital Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals by 33.3% in the second quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company's stock valued at $97,200,000 after buying an additional 100,000 shares during the period. 92.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Tolga Tanguler sold 1,469 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the completion of the sale, the executive vice president now directly owns 13,191 shares in the company, valued at $3,310,677.18. This represents a 10.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CMO Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $422,148.36. Following the transaction, the chief marketing officer now directly owns 17,457 shares in the company, valued at $4,381,357.86. The trade was a 8.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 8,370 shares of company stock worth $2,100,703 in the last ninety days. Company insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY traded up $4.45 during midday trading on Friday, reaching $256.26. 574,959 shares of the company were exchanged, compared to its average volume of 867,049. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The stock has a market cap of $33.05 billion, a P/E ratio of -96.11 and a beta of 0.32. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The stock's 50-day moving average price is $269.49 and its 200-day moving average price is $243.89.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to analysts' expectations of $532.91 million. During the same period in the previous year, the company earned $1.15 EPS. The company's revenue was down 33.3% on a year-over-year basis. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently issued reports on ALNY. Cantor Fitzgerald restated a "neutral" rating and set a $220.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Barclays boosted their price objective on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an "overweight" rating in a research report on Friday, November 1st. Raymond James lifted their target price on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an "outperform" rating in a research report on Friday, November 1st. HC Wainwright reiterated a "buy" rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Finally, The Goldman Sachs Group upgraded Alnylam Pharmaceuticals from a "neutral" rating to a "buy" rating and increased their price objective for the company from $198.00 to $370.00 in a research report on Friday, August 16th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $298.09.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.